3/22/18. The CHMS is encouraging the FDA to keep the Compliance Policy Guide 400.400, entitled “Conditions Under Which Homeopathic Drugs May be Marketed”(CPG 400.400) as it has been, as well as consider homeopathic medicine’s inherently extraordinarily low risk when determining priorities for enforcement of drugs.

Please take the time to submit your constructive comments to the FDA regarding their Draft Guidance on Drug Products Labeled as Homeopathic, issued in December, 2017 by May 21st, 2018.

10/3/17. Read our latest e-news, “Documentary Films Feature Homeopathy + Latest Research” HERE.

For the latest news about homeopathy, and and for political action items, we recommend visiting the website of the National Center for Homeopathy.

Extreme Bias in FTC’s Ruling on Homeopathic Medicine
by Dana Ullman

“In an ongoing effort to undermine homeopathy, the FTC disregards hundreds of peer-reviewed studies and suggests that there is no scientific evidence for these safe, effective therapies.”  Read article

New from the National Health Freedom Coalition

Homeopathy and the Federal Trade Commission: Policies for the 21st Century
by Diane M. Miller JD   Read article